FDA
-
-
-
-
-
-
-
Ocular Therapeutix plans wet AMD drug filing for late 2026
-
-
-
-
-
-
-
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
-
-
-
-
-
-
-
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) PT Lowered to $18 at Needham
-
-
-
-
-
-
-
RBC Capital on Ocular Therapeutix (OCUL): Weakness a Buying Opportunity
-
-
-
-
-
-
-
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
-
-
-
-
-
-
-
Ocular Therapeutix™ to Participate in November and December Investor Conferences
-
328,151 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

